Cite

    Kraus, V. et al. (2019). Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs. Osteoarthritis and cartilage. 27 (4), pp. 571-579. [Online].